详情页

当前位置：首页 > 详情页

Influence of Autophagy Inhibition on Lung Adenocarcinoma Cell Migration and Invasion Ability, and Efficacy of Gefitinib

18| 导出 | 链接全文 |

文献详情

资源类型：

WOS体系：

Pubmed体系：

收录情况： ◇ SCIE

作者：

机构： [1]Hebei Med Univ, Hosp 4, Dept Cytol, Jiankang Rd 12, Shijiazhuang, Hebei, Peoples R China

出处：

DOI：

ISSN：

关键词： autophagy EGFR lung cancer

摘要：

An increasing number of studies have emphasized the role of autophagy in cancer cell metastasis and treatment of malignant tumors. Autophagy inhibitors have been widely used in combination therapies to treat advanced malignancies. Several lung adenocarcinoma cells harbor epidermal growth factor receptor (EGFR) gene mutations, and EGFR tyrosine kinase inhibitors (TKIs) are routinely used in the treatment of lung adenocarcinoma. However, a number of lung adenocarcinoma tumors do not respond or develop resistance to EGFR TKIs. The aim of the present study was to explore the effect of autophagy inhibition on the biological behavior of lung adenocarcinoma cells. In addition, whether autophagy inhibition increases the efficacy of gefitinib in lung adenocarcinoma was investigated. The activation of autophagy was inhibited via the reduction of the expression of ATG5 in A549, H1975 and HCC827 cells. ATG5 knockdown using ATG5 siRNA partially suppressed the LC3B-II expression, decreased the LC3B-I/II conversion rate and enhanced the P62 expression. Cell scratch test and Transwell assay showed that the inhibition of autophagy could impair the migration and invasion ability of cells. These studies suggested that autophagy may play a pro-survival role in lung adenocarcinoma.

语种：

被引次数：

WOS：

PubmedID：

中科院分区：

出版当年[2021]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

最新[2025]版：

大类 | 4 区医学

小类 | 4 区肿瘤学

JCR分区：

出版当年[2021]版：

Q4 ONCOLOGY

最新[2024]版：

Q2 ONCOLOGY

影响因子： 2.8 最新[2024版] 2.5 最新五年平均 2.876 出版当年[2021版] 2.778 出版当年五年平均 3.399 出版前一年[2020版] 2.8 出版后一年[2022版]

第一作者：

第一作者机构： [1]Hebei Med Univ, Hosp 4, Dept Cytol, Jiankang Rd 12, Shijiazhuang, Hebei, Peoples R China

通讯作者：

通讯机构： [1]Hebei Med Univ, Hosp 4, Dept Cytol, Jiankang Rd 12, Shijiazhuang, Hebei, Peoples R China [*1]Department of Cytology, The Fourth Hospital of Hebei Medical University, Jiankang Road 12 Shijiazhuang, Hebei Province, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

相关文献

[1]沉默表皮生长因子受体的表达对肺腺癌A549细胞自噬的影响 [2]晚期非小细胞肺癌患者恶性胸水中表皮生长因子受体的突变检测 [3]Role and mechanism of action of LAPTM4B in EGFR-mediated autophagy [4]Ivonescimab Plus Chemotherapy in Non-Small Cell Lung Cancer With EGFR Variant A Randomized Clinical Trial [5]Clinicopathological features of patients with transformation from EGFR mutant lung adenocarcinoma to small cell lung cancer [6]Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib [7]Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study [8]Adjuvant EGFR-TKI therapy in resected EGFR-mutation positive non-small cell lung cancer: A real-world study [9]7例肺腺癌转化小细胞癌患者的临床病理特征分析 [10]DZD9008 in Pretreated Lung Cancer Patients With EGFR Exon20 Insertion Mutation